Concepedia

Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors

Dieter Dorsch, Oliver Schadt, Frank Stieber, Michael Meyring, Ulrich Grädler, Friedhelm Bladt, Manja Friese‐Hamim, Christine Knühl, Ulrich Pehl, Andree Blaukat

Bioorganic & Medicinal Chemistry Letters · 2015 · 89 citations · 11 references

DOIFull text

Open access

Concepts

References

11

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Alexa B. Turke, Kreshnik Zejnullahu, Yi‐Long Wu et al. · Cancer Cell · 2010 · 1.1K citations · Full text

, , +16

Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a

Nikolaus Schiering, Stefan Knapp, M. Marconi et al. · Proceedings of the National Academy of Sciences · 2003 · 153 citations · Full text

, , +17

EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors

Friedhelm Bladt, Bettina Faden, Manja Friese‐Hamim et al. · Clinical Cancer Research · 2013 · 144 citations · Full text

, , +15

Discovery of (<i>S</i>)-1-(1-(Imidazo[1,2-<i>a</i>]pyridin-6-yl)ethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

Hong Jia, Guangxiu Dai, Jianyang Weng et al. · Journal of Medicinal Chemistry · 2014 · 134 citations · Full text

, , +9

Design, Synthesis, and Pharmacological Evaluation of<i>N</i>-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors

Arthur Eugen Kümmerle, Martine Schmitt, Suzana V.S. Cardozo et al. · Journal of Medicinal Chemistry · 2012 · 120 citations · Full text

, , +13